CannLabs, Inc. (CANL)

CannLabs, Inc. (CANL) — VMCI valuation read

CANL prints VMCI 68/100 inside the Healthcare sector, where the median sits at 50. The 18-point above-median delta is the cleanest single-number summary of CannLabs, Inc.'s composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On CANL, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** CANL trades at 18.0x earnings, 0% above the Healthcare median of 18.0x; that is the value line. ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 0.9x leaves covenant headroom; that is the risk line for CannLabs, Inc. on the trailing financials.

CANL fell 3.3% over the trailing 7 days, with a -17.6% read on a 30-day basis.